SCHEMBL9894619

SCHEMBL9894619

CC=C(C(=O)OC)c1ccccc1COc1cccc(OCc2ccncc2)c1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 7/20 0.58
GPR132 Q9UNW8 1/20 0.44
ABCB1 P08183 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
NOS3 P29474 1/20 0.42
NOS1 P29475 1/20 0.42
NOS2 P35228 1/20 0.42
MEN1 O00255 1/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42
KMT2A Q03164 1/20 0.42
TLR4 O00206 1/20 0.42
TLR2 O60603 1/20 0.42
SLC2A1 P11166 1/20 0.41
SLC2A4 P14672 1/20 0.41
MAOB P27338 1/20 0.41
GRK2 P25098 1/20 0.41
GRK5 P34947 1/20 0.41
GRK3 P35626 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9895203 0.93 HIF1A (0.49) HIF1AABCB1MEN1KMT2A
SCHEMBL9894617 0.92 HIF1A (0.56) HIF1AGPR132ABCB1SMN1; SMN2NOS3
SCHEMBL9894618 0.92 HIF1A (0.56) HIF1AGPR132ABCB1SMN1; SMN2NOS3
SCHEMBL9894620 0.92 HIF1A (0.56) HIF1AGPR132ABCB1SMN1; SMN2NOS3
SCHEMBL9895097 0.91 HIF1A (0.69) HIF1AMAOB
SCHEMBL9894788 0.85 HIF1A (0.50) HIF1AGPR132ABCB1SMN1; SMN2TLR4
SCHEMBL9895200 0.84 HIF1A (0.48) HIF1AABCB1
SCHEMBL9895202 0.84 HIF1A (0.48) HIF1AABCB1
SCHEMBL9895204 0.84 HIF1A (0.48) HIF1AABCB1
SCHEMBL9894890 0.84 HIF1A (0.67) HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8772290-B2 Alpha-arylmethoxyacrylate derivative, preparation method thereof, and pharmaceutical composition containing same Oscotech Inc. (KR) 2014-07-08 US claimed
EP-2565180-A2 ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Oscotec Inc. (KR) 2013-03-06 EP claimed
US-20120149707-A1 ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME OSCOTEC INC. (KR) 2012-06-14 US claimed
US-8772290-B2 Alpha-arylmethoxyacrylate derivative, preparation method thereof, and pharmaceutical composition containing same Oscotech Inc. (KR) 2014-07-08 US disclosed
EP-2565180-A2 ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Oscotec Inc. (KR) 2013-03-06 EP disclosed
US-20120149707-A1 ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME OSCOTEC INC. (KR) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149707-A1 ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME HIF1A, HIF1AN, EGLN3 HIF1A 1/4885GPR132 1841/4885ABCB1 529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.